Garry E. Menzel, Ph.D.

Garry E. Menzel, Ph.D.

DirectoratStoke Therapeutics· In proxies 2023–2025

Garry E. Menzel, Ph.D. sits on 6 public boards.

Boards2

  • Black Diamond TherapeuticsDirector · 8 yr on the boardIndependentAudit (Chair), Compensation—Paid as an executive
  • Stoke TherapeuticsDirector · 4 yr on the boardIndependentAudit, Compensation—Paid as an executive

Board seats come from each company's latest proxy statement.

Experience

  1. Stoke TherapeuticsPublic company · 3 yr
    • Director2023 – Present · 3 yrStock in role +222%
  2. Black Diamond TherapeuticsPublic company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years
  3. AdaptimmunePublic company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years
  4. Black Diamond Therapeutics, Inc.Public company · 12 yr
    • Director2014 – Present · 12 yrNo stock prices for these years
  5. Adaptimmune TherapeuticsPublic company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?